IGM Biosciences Inc [IGMS] stock prices are down -2.31% to $1.27 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IGMS shares have lost -0.78% over the last week, with a monthly amount drifted -5.93%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
IGM Biosciences Inc [NASDAQ: IGMS] stock has seen the most recent analyst activity on January 10, 2025, when Stifel downgraded its rating to a Hold and also revised its price target to $2.50 from $27. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on January 10, 2025, and dropped its price target to $1.50. On January 10, 2025, downgrade downgraded it’s rating to Underweight and revised its price target to $2 on the stock. Guggenheim downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2 on January 10, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on December 06, 2024, and assigned it a price target of $21. In a note dated October 01, 2024, Truist downgraded a Hold rating on this stock and revised its target price from $24 to $12.
The stock price of IGM Biosciences Inc [IGMS] has been fluctuating between $0.92 and $22.50 over the past year. Currently, Wall Street analysts expect the stock to reach $16.79 within the next 12 months. IGM Biosciences Inc [NASDAQ: IGMS] shares were valued at $1.27 at the most recent close of the market. An investor can expect a potential return of 1222.05% based on the average IGMS price forecast.
Analyzing the IGMS fundamentals
The IGM Biosciences Inc [NASDAQ:IGMS] reported sales of 145.05M for trailing twelve months, representing a surge of 11353.19%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.19%, Pretax Profit Margin comes in at -0.37%, and Net Profit Margin reading is -0.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.93 and Total Capital is -0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2600 points at the first support level, and at 1.2500 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2900, and for the 2nd resistance point, it is at 1.3100.
Ratios To Look Out For
It’s worth pointing out that IGM Biosciences Inc [NASDAQ:IGMS]’s Current Ratio is 17.66. In addition, the Quick Ratio stands at 17.66 and the Cash Ratio stands at 5.06. Considering the valuation of this stock, the price to sales ratio is 0.54, the price to book ratio is 0.76.
Transactions by insiders
Recent insider trading involved Tahir Misbah, CHIEF FINANCIAL OFFICER, that happened on Jul 23 ’25 when 8741.0 shares were sold. Chief Executive Officer, Harler Mary Beth completed a deal on Jul 23 ’25 to sell 14501.0 shares. Meanwhile, CHIEF BUSINESS OFFICER Decker Lisa Lynn sold 4409.0 shares on Jul 23 ’25.
